Feature|Videos|September 26, 2025
The Secrets of Successful Drug Launches: The Six Root Causes of New Product Launch Failure, Part 2
Jason O’Neill, author of 'The Secrets of Successful Drug Launches' and former Dendreon CEO, continues his conversation about launch failures, this time detailing unrealistic launch forecasts, underinvestment in preparing the market, and a lack of valuable follow-on instructions can hurt a launch.
Advertisement
Advertisement
Related to this article
Digital health's point-solution era is giving way to broader platforms, and the cost-savings claims those platforms make to employers often don't hold up to methodological scrutiny.
Numerof's Michael Abrams on why directing employees to the most effective, economical clinicians is digital health's most valuable offering.
Numerof's Michael Abrams on why digital health's cost-savings claims often don't hold up to scrutiny — and why the evidence gap matters.
Compounding pharmacies that set their own safety and accreditation standards now stand the best chance of keeping patient access intact before heavier regulation does it for them.
Numerof's Michael Abrams on why digital health's point-solution era is ending — and why consolidation into broader platforms is the next step.
FDA has approved Welireg plus Lenvima for previously treated advanced clear cell renal cell carcinoma.
Six years after Rutledge, new court rulings, federal PBM reforms, and state ownership bans are redrawing the limits of pharmacy benefit regulation.
Numerof's Michael Abrams on why healthcare consolidation is the primary driver of rising employer costs — and why there's no end in sight.
Advertisement
Advertisement
Trending on PharmExec
1
Pharmaceutical Executive Daily: Foghorn Therapeutics & Eli Lilly Discontinue Development of FHD-909
2
Roundup: Novartis & Abogen Enter Licensing and Option Agreement, AstraZeneca and Daiichi Sankyo Enter Clinical Collaboration with Summit Therapeutics
3
New U.S. Guidance Lays Out Exemptions for 100% Tariffs: Report
4
Foghorn Therapeutics & Eli Lilly Halt Fhd-909 Development Following Phase I Data
5